New treatment strategies are urgently needed: in this regard, the estrogen receptor degraders (SERDs) aim to block the ER pathway, and some clinical trials on metastatic BC are ongoing (NCT02248090, NCT2338349). The gene discussed is ESR1; the disease is breast cancer.